Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors tha… Read more
Perspective Therapeutics Inc. (CATX) - Net Assets
Latest net assets as of September 2025: $242.22 Million USD
Based on the latest financial reports, Perspective Therapeutics Inc. (CATX) has net assets worth $242.22 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($294.82 Million) and total liabilities ($52.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $242.22 Million |
| % of Total Assets | 82.16% |
| Annual Growth Rate | 25.34% |
| 5-Year Change | 374.35% |
| 10-Year Change | 4978.94% |
| Growth Volatility | 193.68 |
Perspective Therapeutics Inc. - Net Assets Trend (1994–2024)
This chart illustrates how Perspective Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Perspective Therapeutics Inc. (1994–2024)
The table below shows the annual net assets of Perspective Therapeutics Inc. from 1994 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $290.67 Million | +286.63% |
| 2023-12-31 | $75.18 Million | +37.58% |
| 2023-06-30 | $54.64 Million | 0.00% |
| 2022-12-31 | $54.64 Million | -10.83% |
| 2022-06-30 | $61.28 Million | 0.00% |
| 2021-12-31 | $61.28 Million | -9.09% |
| 2021-06-30 | $67.41 Million | +427.72% |
| 2020-12-31 | $12.77 Million | +123.19% |
| 2020-06-30 | $5.72 Million | 0.00% |
| 2019-12-31 | $5.72 Million | -25.48% |
| 2019-06-30 | $7.68 Million | 0.00% |
| 2018-12-31 | $7.68 Million | +52.68% |
| 2018-06-30 | $5.03 Million | -52.56% |
| 2017-12-31 | $10.60 Million | 0.00% |
| 2017-06-30 | $10.60 Million | -35.36% |
| 2016-12-31 | $16.40 Million | 0.00% |
| 2016-06-30 | $16.40 Million | -21.08% |
| 2015-12-31 | $20.78 Million | 0.00% |
| 2015-06-30 | $20.78 Million | -13.25% |
| 2014-12-31 | $23.96 Million | 0.00% |
| 2014-06-30 | $23.96 Million | +346.42% |
| 2013-12-31 | $5.37 Million | 0.00% |
| 2013-06-30 | $5.37 Million | -7.77% |
| 2012-12-31 | $5.82 Million | 0.00% |
| 2012-06-30 | $5.82 Million | -9.83% |
| 2011-12-31 | $6.45 Million | 0.00% |
| 2011-06-30 | $6.45 Million | +4.14% |
| 2010-12-31 | $6.20 Million | 0.00% |
| 2010-06-30 | $6.20 Million | -37.81% |
| 2009-12-31 | $9.96 Million | 0.00% |
| 2009-06-30 | $9.96 Million | -36.84% |
| 2008-12-31 | $15.77 Million | 0.00% |
| 2008-06-30 | $15.77 Million | -30.56% |
| 2007-12-31 | $22.72 Million | 0.00% |
| 2007-06-30 | $22.72 Million | +687.20% |
| 2006-12-31 | $2.89 Million | 0.00% |
| 2006-06-30 | $2.89 Million | -74.31% |
| 2005-06-30 | $11.23 Million | 0.00% |
| 2004-12-31 | $11.23 Million | +2090.78% |
| 2004-06-30 | $-564.20K | +47.90% |
| 2003-12-31 | $-1.08 Million | 0.00% |
| 2003-06-30 | $-1.08 Million | -4.89% |
| 2002-12-31 | $-1.03 Million | 0.00% |
| 2002-06-30 | $-1.03 Million | +19.48% |
| 2001-12-31 | $-1.28 Million | -4.76% |
| 2000-12-31 | $-1.22 Million | +4.54% |
| 2000-06-30 | $-1.28 Million | +39.95% |
| 1999-12-31 | $-2.14 Million | -74.46% |
| 1999-06-30 | $-1.22 Million | +40.91% |
| 1998-12-31 | $-2.07 Million | +2.99% |
| 1998-06-30 | $-2.14 Million | -12.23% |
| 1997-12-31 | $-1.90 Million | +8.15% |
| 1997-06-30 | $-2.07 Million | -221.95% |
| 1996-12-31 | $-643.46K | +66.18% |
| 1996-06-30 | $-1.90 Million | -743.43% |
| 1995-12-31 | $295.71K | +145.96% |
| 1995-06-30 | $-643.46K | -317.59% |
| 1994-12-31 | $295.71K | 0.00% |
| 1994-06-30 | $295.71K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Perspective Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22832364600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $70.00K | 0.02% |
| Other Comprehensive Income | $-51.00K | -0.02% |
| Other Components | $522.37 Million | 179.71% |
| Total Equity | $290.67 Million | 100.00% |
Perspective Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Perspective Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SNTEnergy Co Ltd
KO:100840
|
$259.40 Million |
|
Cosmo Chem
KO:005420
|
$259.43 Million |
|
Novogene Co. Ltd.
SHG:688315
|
$259.49 Million |
|
Zhongjin Irradiation Incorporated Company
SHE:300962
|
$259.61 Million |
|
Hubei Yingtong Telecommunication Cable Co Ltd
SHE:002861
|
$259.20 Million |
|
Thai Airways International Public Company Limited
PINK:TAWNF
|
$259.20 Million |
|
Shandong Astro-century Education&Technology Co Ltd
SHE:300654
|
$259.11 Million |
|
Changzhou Kaidi Electrical Inc
SHG:605288
|
$259.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Perspective Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 75,179,000 to 290,668,000, a change of 215,489,000 (286.6%).
- Net loss of 79,279,000 reduced equity.
- New share issuances of 275,932,000 increased equity.
- Other comprehensive income decreased equity by 51,000.
- Other factors increased equity by 18,887,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-79.28 Million | -27.27% |
| Share Issuances | $275.93 Million | +94.93% |
| Other Comprehensive Income | $-51.00K | -0.02% |
| Other Changes | $18.89 Million | +6.5% |
| Total Change | $- | 286.63% |
Book Value vs Market Value Analysis
This analysis compares Perspective Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.81x to 1.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-06-30 | $1.03 | $4.95 | x |
| 1995-06-30 | $-2.24 | $4.95 | x |
| 1995-12-31 | $1.03 | $4.95 | x |
| 1996-06-30 | $-6.62 | $4.95 | x |
| 1996-12-31 | $-2.24 | $4.95 | x |
| 1997-06-30 | $-6.38 | $4.95 | x |
| 1997-12-31 | $-5.86 | $4.95 | x |
| 1998-06-30 | $-6.49 | $4.95 | x |
| 1998-12-31 | $-6.29 | $4.95 | x |
| 1999-06-30 | $-3.72 | $4.95 | x |
| 1999-12-31 | $-6.49 | $4.95 | x |
| 2000-12-31 | $-3.72 | $4.95 | x |
| 2001-12-31 | $-3.89 | $4.95 | x |
| 2002-06-30 | $-3.14 | $4.95 | x |
| 2002-12-31 | $-3.14 | $4.95 | x |
| 2003-06-30 | $-3.29 | $4.95 | x |
| 2003-12-31 | $-3.29 | $4.95 | x |
| 2004-06-30 | $-0.70 | $4.95 | x |
| 2004-12-31 | $2.00 | $4.95 | x |
| 2005-06-30 | $4.76 | $4.95 | x |
| 2006-06-30 | $0.24 | $4.95 | x |
| 2006-12-31 | $0.24 | $4.95 | x |
| 2007-06-30 | $1.27 | $4.95 | x |
| 2007-12-31 | $1.27 | $4.95 | x |
| 2008-06-30 | $0.69 | $4.95 | x |
| 2008-12-31 | $0.69 | $4.95 | x |
| 2009-06-30 | $0.43 | $4.95 | x |
| 2009-12-31 | $0.43 | $4.95 | x |
| 2010-06-30 | $0.27 | $4.95 | x |
| 2010-12-31 | $0.27 | $4.95 | x |
| 2011-06-30 | $0.26 | $4.95 | x |
| 2011-12-31 | $0.26 | $4.95 | x |
| 2012-06-30 | $0.20 | $4.95 | x |
| 2012-12-31 | $0.20 | $4.95 | x |
| 2013-06-30 | $0.16 | $4.95 | x |
| 2013-12-31 | $0.16 | $4.95 | x |
| 2014-06-30 | $0.56 | $4.95 | x |
| 2014-12-31 | $0.56 | $4.95 | x |
| 2015-06-30 | $0.38 | $4.95 | x |
| 2015-12-31 | $0.38 | $4.95 | x |
| 2016-06-30 | $0.30 | $4.95 | x |
| 2016-12-31 | $0.30 | $4.95 | x |
| 2017-06-30 | $0.19 | $4.95 | x |
| 2017-12-31 | $0.19 | $4.95 | x |
| 2018-06-30 | $0.09 | $4.95 | x |
| 2018-12-31 | $0.11 | $4.95 | x |
| 2019-06-30 | $0.11 | $4.95 | x |
| 2019-12-31 | $0.08 | $4.95 | x |
| 2020-06-30 | $0.08 | $4.95 | x |
| 2020-12-31 | $0.23 | $4.95 | x |
| 2021-06-30 | $0.65 | $4.95 | x |
| 2021-12-31 | $4.31 | $4.95 | x |
| 2022-06-30 | $0.43 | $4.95 | x |
| 2022-12-31 | $1.00 | $4.95 | x |
| 2023-06-30 | $0.38 | $4.95 | x |
| 2023-12-31 | $1.37 | $4.95 | x |
| 2024-12-31 | $4.51 | $4.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Perspective Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-27.27%) is above the historical average (-44.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | -147.98% | -6.45% | 2.36x | 9.73x | $-467.17K |
| 1995 | 0.00% | -6.45% | 3.46x | 0.00x | $-373.25K |
| 1995 | -147.98% | -6.45% | 2.36x | 9.73x | $-467.17K |
| 1996 | 0.00% | -12.01% | 4.49x | 0.00x | $-748.90K |
| 1996 | 0.00% | -12.01% | 3.98x | 0.00x | $-874.82K |
| 1997 | 0.00% | -26.06% | 6.29x | 0.00x | $-1.94 Million |
| 1997 | 0.00% | -26.06% | 4.74x | 0.00x | $-1.96 Million |
| 1998 | 0.00% | -5.43% | 6.68x | 0.00x | $-212.53K |
| 1998 | 0.00% | -5.43% | 5.98x | 0.00x | $-218.92K |
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.14K |
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $74.00K |
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $1.95 Million |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $62.58K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $37.60K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $338.36K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $49.22K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $49.22K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.61K |
| 2004 | -38.01% | -2116.28% | 0.01x | 2.90x | $-5.39 Million |
| 2005 | 0.67% | 0.00% | 0.00x | 2.90x | $-1.05 Million |
| 2006 | -284.79% | -412.08% | 0.35x | 1.96x | $-8.51 Million |
| 2006 | -284.79% | -412.08% | 0.35x | 1.96x | $-8.51 Million |
| 2007 | -42.28% | -167.39% | 0.22x | 1.15x | $-11.88 Million |
| 2007 | -42.28% | -167.39% | 0.22x | 1.15x | $-11.88 Million |
| 2008 | -54.25% | -119.54% | 0.40x | 1.13x | $-10.13 Million |
| 2008 | -54.25% | -119.54% | 0.40x | 1.13x | $-10.13 Million |
| 2009 | -61.84% | -113.71% | 0.46x | 1.18x | $-7.16 Million |
| 2009 | -61.84% | -113.71% | 0.46x | 1.18x | $-7.16 Million |
| 2010 | -65.11% | -76.31% | 0.67x | 1.28x | $-4.65 Million |
| 2010 | -65.11% | -76.31% | 0.67x | 1.28x | $-4.65 Million |
| 2011 | -44.05% | -54.25% | 0.66x | 1.22x | $-3.49 Million |
| 2011 | -44.05% | -54.25% | 0.66x | 1.22x | $-3.49 Million |
| 2012 | -59.97% | -68.80% | 0.68x | 1.29x | $-4.07 Million |
| 2012 | -59.97% | -68.80% | 0.68x | 1.29x | $-4.07 Million |
| 2013 | -71.87% | -85.22% | 0.64x | 1.31x | $-4.39 Million |
| 2013 | -71.87% | -85.22% | 0.64x | 1.31x | $-4.39 Million |
| 2014 | -24.88% | -141.24% | 0.16x | 1.11x | $-8.35 Million |
| 2014 | -24.88% | -141.24% | 0.16x | 1.11x | $-8.35 Million |
| 2015 | -17.71% | -79.91% | 0.20x | 1.11x | $-5.76 Million |
| 2015 | -17.71% | -79.91% | 0.20x | 1.11x | $-5.76 Million |
| 2016 | -28.72% | -98.77% | 0.26x | 1.10x | $-6.35 Million |
| 2016 | -28.72% | -98.77% | 0.26x | 1.10x | $-6.35 Million |
| 2017 | -58.12% | -129.43% | 0.39x | 1.16x | $-7.22 Million |
| 2017 | -58.12% | -129.43% | 0.39x | 1.16x | $-7.22 Million |
| 2018 | -133.20% | -113.12% | 0.79x | 1.48x | $-7.20 Million |
| 2018 | -63.15% | -66.31% | 0.78x | 1.23x | $-5.62 Million |
| 2019 | -63.15% | -66.31% | 0.78x | 1.23x | $-5.62 Million |
| 2019 | -57.12% | -33.77% | 1.11x | 1.52x | $-3.84 Million |
| 2020 | -57.12% | -33.77% | 1.11x | 1.52x | $-3.84 Million |
| 2020 | -24.96% | -31.71% | 0.65x | 1.21x | $-4.47 Million |
| 2021 | -4.73% | -31.71% | 0.14x | 1.04x | $-9.93 Million |
| 2021 | -11.87% | -67.36% | 0.17x | 1.05x | $-13.40 Million |
| 2022 | -11.67% | -66.26% | 0.17x | 1.05x | $-13.28 Million |
| 2022 | -26.85% | -206.50% | 0.12x | 1.06x | $-20.13 Million |
| 2023 | -26.85% | -206.50% | 0.12x | 1.06x | $-20.13 Million |
| 2023 | -61.86% | -3243.24% | 0.01x | 1.30x | $-54.03 Million |
| 2024 | -27.27% | 0.00% | 0.00x | 1.17x | $-108.35 Million |
Industry Comparison
This section compares Perspective Therapeutics Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Perspective Therapeutics Inc. (CATX) | $242.22 Million | -147.98% | 0.22x | $259.26 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |